Organon Secures License for Sebela’s MIUDELLA Hormone-Free Intrauterine Device
Organon signed a licensing agreement to acquire global development and commercialization rights for MIUDELLA, Sebela Pharmaceuticals' hormone-free intrauterine device. This deal expands Organon's contraceptive portfolio by adding a non-hormonal IUD option targeting women seeking alternative birth control.
1. License Agreement Details
Organon entered a licensing agreement to obtain global rights to develop, manufacture and commercialize MIUDELLA, Sebela Pharmaceuticals' hormone-free intrauterine device. Terms of the agreement, including upfront payments, milestone fees and royalty rates, were not disclosed.
2. Strategic Impact
The addition of a non-hormonal IUD broadens Organon's women’s health portfolio by addressing patient demand for hormone-free contraceptive solutions, potentially strengthening the company’s position in the reproductive health market.